Vancomycin Dosage Strategy Based on a Trough Concentration Model
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Sep 11, 2019
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective randomized control trial. There are two groups, study group and control group. Patients of study group accepted vancomycin strategies decided by a serum trough concentration model, and patients of control group accepted vancomycin dosage decided by attending physician. The primary endpoint is the incidence of reaching the target serum trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side effects such as acute kidney injury, etc.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with doubted or diagnosed Methicillin-resistant Staphylococcus aureus severe pneumonia, and need vancomycin treatment.
- • Sixty years and older.
- Exclusion Criteria:
- • younger than 60 years old
- • Accepted blood purification therapy
- • Pregnancy
- • Positive HIV antibody titre
- • Had known or suspected tuberculosis or other infections caused by fungi at baseline.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Qingtao Zhou, Dr.
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials